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Novel formulations of the halogenated corticosteroid, triamcinolone-acetonide, based on ultradeformable mixed lipid vesicles,
TransfersomesR, are described. Their performance was tested in vivo using radioactive label measurements, to study the drug biodistribution,
and murine ear edema, to determine the drug bioactivity. Sparse use of drug-loaded TransfersomesR on the skin ensures an almost exclusive
delivery of triamcinolone-acetonide into the organ, thus arguably increasing the treatment safety. Delivery of triamcinolone-acetonide in the
skin with ultradeformable vesicles prolongs the anti-inflammatory drug action several times compared to drug usage in a conventional cre`me
or an ointment, the robustness of biological response for the former being at least identical to the latter. The required dose of TransfersomeR-
based triamcinolone-acetonide is also greatly reduced. The drug dose of 0.2 Ag cm 2 suppresses 75% of arachidonic acid-induced murine ear
edema for at least 48 h. In contrast, a conventional formulation of triamcinolone-acetonide requires a 10-fold higher drug dosage to achieve a
similar effect. In either case, increasing the applied corticosteroid amount delays the onset of anti-edema action.D 2003 Published by Elsevier B.V.Keywords: Improved dermatic; Ultradeformable vesicle; Targeted delivery; Topical application; TransfersomeR, triamcinolone-acetonide1. Introduction
Approximately one-third of all dermatics contain cortico-
steroids. Such drugs are also widely used for systemic
medication [1]. Unfortunately, all biogenic, natural (gluco)-
corticosteroids exert only rather short and weak action in
vivo. To improve the situation, synthetic (halogenated)
corticosteroids were introduced. The synthetic derivatives
are more potent than their natural kin and have a longer
duration of action, but are burdened by increased risk of
adverse effects [1]. This is true for dexamethasone, pred-
nisolone, triamcinolone, their derivatives, and many related
drugs.
Side effects are most probable when halogenated cortico-
steroids are repeatedly used on the skin. This often neces-
sitates the discontinuation of a therapy performed with
synthetic corticosteroids, mainly due to severe skin thin-
ning. The drug-induced skin atrophy is due largely to the
catabolic and anti-proliferative actions of corticosteroids0005-2736/03/$ - see front matter D 2003 Published by Elsevier B.V.
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1 Address during the study.that are also responsible for most of the drug’s anti-inflam-
matory action.
It appears that a measure of a corticosteroid’s potency as
a glucocorticoid is the degree of inhibition of corticotropin
secretion it produces [1]. Local corticotropin inhibition is
also observed, and has prompted attempts to improve the
local biodistribution and action of corticosteroids by galenic
means. Most modern corticosteroid dermatics therefore
contain substances that partition into the skin, and act as
skin permeation enhancers [2]. Drug supersaturation also
increases the (thermodynamic) activity of locally applied
therapeutics activity [3] but is burdened with metastability.
Corticosteroid incorporation into lipid vesicles (lipo-
somes) and topical administration of the resulting formula-
tion has been claimed by some authors to increase the drug
concentration in the skin [4–10], but other authors observed
just the opposite [11]. Deviant results have also been
reported for the therapeutic benefit of liposome-based cor-
ticosteroid dermatics [12]. This may explain why no corti-
costeroid product containing liposomes has reached the
market.
We developed self-regulating drug carriers, so-called
TransfersomesR (‘carrying bodies’, a trademark of IDEA
AG), specifically to overcome the skin barrier. Such carriers
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junction with liposomes [13–16].
TransfersomesR overcome the skin barrier by opening
extracellular pathways between cells in the organ and then
deforming to fit into such passages. In the process, Trans-
fersomesR undergo a series of stress-dependent adjustments
of the local carrier composition to minimise the resistance of
motion through the otherwise confining channel [16]. This
allows TransfersomesR to transport the drugs associated
into and across the skin easily and very reproducibly. This
happens at a rate substantially higher than that achieved by
more conventional topical corticosteroid formulations and
offers excellent means for controlling drug distribution in
the skin [17].
In this paper, we present the results of biological tests with
an intermediate potency synthetic corticosteroid, triamcino-
lone-acetonide, with a potency of 2 relative to hydrocorti-
sone (which has a nominal potency of 1) [35]. We compare
triamcinolone-acetonide in TransfersomesR with a commer-
cial ointment and a cre`me, using a lower intrinsic drug
concentration in the former type of formulation.
In the currently used commercial products based on a
lotion, cre`me or an ointment, triamcinolone-acetonide is
usually used at a concentration in the order of 0.1 wt.% [1].
To determine relative potency of our novel triamcinolone-
acetonide formulation, we used different agent concentra-
tions in appropriate carriers and then tested the apparent
biological potency of the product. As a secondary question,
the effect of TransfersomeR-mediated delivery on drug
biodistribution in the skin and on the anticipated risk/benefit
ratio was assessed.
Topical usage of triamcinolone-acetonide with Trans-
fersomesR was found to reduce the necessary drug dosage
to the levels of 0.01 wt.%. Epicutaneous drug administration
in these highly deformable carriers was also observed to
prolong markedly the biological response time and to
increase the reproducibility of the biological drug action.
These results further illustrate the advantages and varied
uses of the TransfersomeR delivery system for triamcino-
lone-acetonide [18] and for other corticosteroids.2. Materials and methods
All substances used in the study were of pharmaceutical
quality. Soybean phosphatidylcholine (SPC) was purchased
from Nattermann Phospholipids-Aventis (Cologne, Ger-
many) or from Lipoid KG (Ludwigshafen, Germany); in
both cases, its purity exceeded 95%. The remaining com-
ponents, which rendered carrier membranes more deform-
able, were obtained from Henkel (Du¨sseldorf, Germany).
They were typically of the polysorbate type and are de-
scribed in detail in Ref. [13].
The corticosteroid derivative triamcinolone-acetonide
was purchased in pharmaceutical quality from SynoPharm
(Hamburg, Germany). Injectable quality bi-distilled waterwas purchased from the local pharmacy, as were the
commercial drug formulations used as experimental con-
trols. Triamcinolone-acetonide in a lotion or a cre`me
(Volon AR lotion or cre`me, respectively; Squibb-Hayden,
Munich, Germany) or in a different cre`me (Delphicort;
Lederle, Wolfratshausen, Germany) were used for the
purpose.
2.1. Sample preparation
The formulations used in biodistribution studies were
labelled with triturated corticosteroids purchased from
Amersham or ICN. To prepare such formulations for use
in animals, all lipids were dissolved in methanol/chloroform
(1:1 v/v) in the appropriate amounts and a dry-mixed lipid
film was prepared under vacuum (10 Pa; 12 h).
Formulations contained between 0.005 and 0.5 wt.%
corticosteroids per ml of carrier suspension. The latter
consisted chiefly of phosphatidylcholine (SPC) in the final
concentration between 0.5 and 5 wt.%. Except when stated
otherwise, the lipid was introduced as an ethanolic solution
(SPC/EtOH= 1:1 w/v). SPC lipid was taken up in a buffer
with pH = 6.5 and homogenised by sonication (titanium
micro-tip, Heat Systems W 380, USA, 4 jC) or other
mechanical means for the manufacture of human therapeu-
tics to achieve the desired vesicle size. The final vesicle size
was determined with photon correlation spectroscopy
(ALV-5000 Laser, ALV-Laser Vertriebsgesellschaft, Lan-
gen, Germany) and was typically between 100 and 200
nm. In experimental situations, the lipid suspension was
diluted appropriately, if required, maintaining pH around
6.5.
At least one of the carrier components was characterised
by its membrane solubilising capacity, as is required by the
basic rationale of the TransfersomeR design [13]. Typically,
polysorbate 80 was used, which was included in the
formulation at 9:11 w/w ratio relative to SPC, except in
one test series in which polysorbate concentration was
doubled. This carrier substance was thus included in the
final medication approximately 10 times below the lytic
concentration, which ensured high carrier deformability
without compromising the integrity of the TransfersomeR
vesicle [15]; the TransfersomesR must have these properties
in order to maximise drug carrier transport across the
stratum corneum [16].
2.2. Animal experiments
Animal trials were performed on 8–12-week-old NMRI
mice, adhering to the ‘‘Principles of Laboratory Animal
Care’’ (NIH publication #85-23, revised in 1985). The
animals were kept under standard laboratory conditions
(three to five animals per suspended cage; standard feed
and water ad libitum; 12 h light/dark regime). A general
anaesthesia was used to keep the test animals stress-free
during the manipulations.
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The hair at the chosen skin site was trimmed to a length
of 2 mm 1 day before the beginning of the experimental
trials using a pair of scissors. The precise application site on
the upper back was marked and the appropriate amount
(0.5–25 Al) of the drug formulation was applied with a
micropipette on the skin. The applied formulation was
uniformly spread on the mouse skin (using the side of the
micropipette tip) and allowed to dry. Tail blood (20 Al) was
collected with a glass capillary. Eight hours after the
application of the drug formulation, the animals were killed
by heart puncture; the treated skin area was undermined, and
then carefully excised. The outermost layers of the stratum
corneum were removed and collected by five sequential
tape-strippings (Tesa-Film; Baiersdorf, Hamburg, Ger-
many). The residual skin tissue and other organ samples
were then excised, de-stained, and used for radioactivity
counting as described earlier [20].
2.2.2. Drug activity in vivo
All animal tests were done in mice. Biological action in
mice is most often tested by measuring the suppression of
the chemically induced edema by the topically administered
corticosteroids. This is an established method for the pur-
pose, which yields relevant results despite the known
difference between human and murine skin properties [19].
In brief, we used a modification of the classical method,
changed so as to avoid killing the animals for the purpose of
measuring their ear thickness [19]. The test animals were
first anaesthetised with an intraperitoneal injection of 10
Al per g body weight of a mixture containing 6 ml 0.9%
NaCl, 1 ml Ketavet 100 (Parke-Davis, Berlin, FRG), and
0.25 ml Rompun (Bayer, Leverkusen, Germany). The ap-
propriate amount of drug formulation was then applied to
the inner side of one ear over an area of 0.8 cm2 and left to
dry. Afterwards, when so stated, the ear was cleaned of
superficial formulation with a dry cotton swab. Each mouse
was anaesthetised before the addition of arachidonic acid in
ethanol (1:2 v/v, 10 Al) to induce ear edema, which typically
just about more than doubled the ear thickness/weight. The
arachidonic acid solution was applied to the same ear area as
the drug formulation.
Changes in mouse ear edema (relative to that of the
untreated, challenged ear) were determined either by mea-
suring the ear thickness with a microcaliper (our modified
method) or by weighing the flexed ear area of the killed
mouse (the original procedure [19]). We obtained similar
results with both methods. All values are the means of at
least three independently measured experiments and bars
represent the standard deviation of the mean. The onset of
edema suppression was defined as the time at which edema
suppression first reached the level of 50%, or the weight
decreased from a maximum around 30 mg (for a 6 mm
tissue disc) to around 22 mg. The half-life for edema
suppression was identified with the latest time point at
which the observed suppression was z 50%. Changes
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therefore excluded from typical data presentation.
2.2.3. Adverse side effects in mice in vivo were assessed
both locally and systemically
The first aim was reached by measuring changes in the
thickness of the treated 1 cm2 skin in a fold on the back of
mice with a caliper and comparing the result with a
comparably prepared, but untreated, remote site on the same
animal. Additionally, the corresponding site on an animal
treated with empty, negative control vesicles was used for
comparison. For the second purpose, changes in body
weight and gross appearance of the test animals were
notified. The drug application was done at the same dosage
(10 Ag cm 2) twice weekly with the drug in Trans-
fersomesR or every day with the commercial cre`me. The
applied dose was thus 10 times too high for the Trans-
fersomeR-based formulation and appropriate for Volon AR.
Judging from the cumulative edema suppression data (cf.
Fig. 4), the appropriate dose/application frequency ratio for
the two formulations should have been 8–15 times lower
rather than 3 times lower for TransfersomesR, to achieve
‘‘equipotency’’. The TransfersomeR-treated group was thus
deliberately overdosed.
Data analyses were performed with the software package
ORIGINR (Microcal, OR). Statistical significance was
determined using the ANOVA test. The specific level of
significance used is given in the text, being typically
Pz 0.05.3. Results
The biodistribution and the pharmacokinetics of triam-
cinolone-acetonide in TransfersomesR administered in vivo
directly to intact murine skin or injected intravenously in
mice were compared in our previous study [17]; both drug
applications gave similar distributions of the drug-derived
radioactivity. In this study, we focused our interest on the in
vivo effects of the administration of triamcinolone-acetonide
in TransfersomesR, using mouse ear edema model for the
purpose. In short, glucocorticosteroid delivery into the skin
with ultradeformable carriers ensured a high degree of drug
localisation, increased the apparent drug potency and pro-
longed duration of drug action, all these changes being
advantageous for dermal therapy.
3.1. Ear edema suppression in mice
The rate and the efficacy of TransfersomeR-mediated
corticosteroid delivery in the skin were first tested for
triamcinolone-acetonide in TransfersomesR in an animal
model. The topical administration of a similar drug in a
cre`me or lotion was used for reference. In general, the agent
was found to act remarkably long compared with the duration
of action of the other corticosteroids that we tested [18].
Fig. 1. Time dependency of the suppression of arachidonic acid-induced ear
edema in mice caused by an epicutaneous administration of triamcinolone-
acetonide in ultradeformable carriers (TransfersomesR; upper panel, closed
symbols) or in a commercial lotion (lower panel, open symbols). Mean
values and their standard error are given.
Fig. 2. Effect of residual drug and vehicle elimination from the skin surface
at different times after a topical treatment with triamcinolone-acetonide in
TransfersomesR (upper panel, closed symbols), in a commercial lotion, or a
cre`me (open down-arrow and up-arrow, respectively, lower panel). Dashed
lines give the corresponding results from Fig. 1 for comparison.
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and prolonged the biological action of topically applied
triamcinolone-acetonide (see Fig. 1). When applied as a
topical lotion, the onset of edema suppression was measured
to be 1.5, 7.6 or 12.5 h for the dosages 0.8, 2, or 20 Ag
cm 2, respectively (Fig. 1, lower panel). In contrast, when
the agent was applied to the murine skin in a TransfersomeR
suspension, the onset of edema suppression was 1.5, 6.2 or
9 h for the dosages 0.2, 0.4, or 0.8 Ag cm 2, respectively
(Fig. 1, upper panel). These times differed up to 20%
between various equidose experiments but are similar when
compared on the basis of quasi-equivalent action. The
reverse dose dependence in temporal terms is a fairly
general but seldom reported property of corticosteroids that
is incompletely understood. We did not attempt to explore
the origin of phenomenon due to our focus on modified
delivery, rather than on drug properties and action.
The maximum duration of drug action following epicuta-
neous administration of the highest tested triamcinolone-
acetonide dosage in TransfersomesR or in a lotion is z 84
and 75 h, respectively. If a similarly low dose is used in the
commercial lotion and in ultradeformable carriers (0.8 Ag
cm 2) the maximum duration of drug action for the former
is merely 2 h, that is, 40 times shorter than for the latter
formulation.
Within the time window of 4–24 h after challenge to the
murine ear, the average magnitude of the edema suppres-
sion is 60F 23% for a dosage of 2 Ag cm 2. The result is
43F 19% for a dosage of 20 Ag cm 2 when the triamcin-
olone-acetonide is in either case applied as a topical lotion.
The magnitude of the edema suppression in an identicaltime window for the tested triamcinolone-acetonide in
TransfersomesR is approximately 10% higher, being
69F 23% for an applied dosage of 0.4 Ag cm 2 and
52F 13% for an applied dosage of 0.8 Ag cm 2. The
overall reproducibility of the results obtained with Trans-
fersomesR is approximately 30% better than that of the
commercially available lotion for the intermediate tested
drug dose; also, the average single time reproducibility is
30% better for the TransfersomesR-based formulation (the
specific results for the intermediate tested dose being
10F 6% and 7F 3%, respectively). Averaged over a 4–
48-h time interval, the average suppression levels are
56F 22% and 70F 18%, respectively.
The observed differences between the equipotent treat-
ments are statistically insignificant at the level of P < 0.1,
when calculated for the first day or the entire observation
period, but become significant at P= 0.08 during the second
day of treatment. The differences between the results of
equidose comparisons are highly significant (P>0.001) at
all times.
The results of the second test series given in Fig. 2 are
very similar to those shown in Fig. 1, except in that the late
time values are somewhat, but not significantly higher
(P < 0.1). The data suggests that triamcinolone-acetonide
after a single administration on the skin in TransfersomesR
is active biologically for more than 96 h, even when the skin
surface is wiped ‘‘clean’’ by cotton swab. The values in Fig.
2 also imply that the drug used at the dose of 20 Ag cm 2 in
a commercial cre`me (Delphicort) may be marginally more
effective than the drug in a lotion (Volon AR Lotion). The
respective average suppression values are 67F 24% and
54F 20% for the 24–96 h period. For the TransfersomeR-
Fig. 4. Dose dependency of triamcinolone-acetonide-induced murine ear
edema suppression 8 h after the drug administration on the skin in
TransfersomesR containing two different polysorbate concentrations
(closed symbols), in a lotion (open circle) or in a cre`me (open boxes).
Straight lines give the results of quasi-linear fit for each individual data set.
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the corresponding average values are 68F 13% and
78F 13% for two different experiments.
The results given in Fig. 3 support the abovementioned
conclusions. The edema suppression mediated by two dif-
ferent types of TransfersomesR related with the outcome of
the skin treatment with triamcinolone-acetonide in similarly
large liposomes or a lotion reveals that the latter two, when
used at an equal dosage, are at least 20 times less effective.
The observed gain in drug efficacy is not explicable by
simple skin permeation enhancement, which is generally
accepted to be negligible for polysorbate [2]. If permeation
enhancement in our study was important, the results
obtained with TransfersomeR formulations with and with-
out ethanol, which is a well established permeation enhancer
[2], would have to be significantly different. Fig. 4 shows
that this is not the case, however.
3.2. Dose dependency
We used the mouse ear edema model to determine the
dose dependency of drug action for the TransfersomeR
formulation versus commercial cre`me and lotion. Triamcin-
olone-acetonide in commercial cre`me exerted a strong
biological effect when dosed at approximately 8 Ag cm 2.
The 50% efficacy level was reached near 2 Ag cm 2 (Fig.
4). In contrast, the TransfersomeR formulation of such drug
was 50% active at a dosage that was 10 times lower (0.2 Ag
cm 2) than that required for the cre`me (1.6 Ag cm 2) or the
slightly less potent lotion (2.6 Ag cm 2; cf. Fig. 4). These
estimates pertain to the results measured 8 h after the skin
challenge with arachidonic acid. Experiments performed atFig. 3. Vehicle sensitivity of murine ear edema suppression by
triamcinolone-acetonide in TransfersomesR (upper panel), in a commercial
lotion (lower panel: open diamonds), or in conventional liposomes with the
size comparable to that of TransfersomesR (lower panel: circles) as a
function of time after an epicutaneous drug administration.1 h after the challenge showed a similar dose dependency
for the TransfersomeR formulations, reaching a maximum
activity of 20%, and a less pronounced, but comparable
effect to that observed with the lotion in the 8-h trials (data
not shown). Trials after 16 h led to qualitatively similar
results with an increase in the edema suppression values to
approximately 80% (data not shown).
We also calculated the area under the curve (AUC) for
the edema suppression, to assess cumulative triamcinolone-
acetonide activity (see Fig. 5). For commercial lotions, theFig. 5. Cumulative dose response to an epicutaneous administration of
triamcinolone-acetonide in TransfersomeR (closed circles) or in lotion
(open circles) based on murine ear edema suppression effects.
Table 1
Adverse side effect of approximately equipotent topical treatment with
triamcinolone-acetonide (TAC) on the skin for 6 weeks in ultradeformable
vesicles (Tfs) or in Volon A cre`me
Formulation TAC dose Change (%)
Ag cm 2
Treated/
remote
Treated/
control
Body
weight
TAC Tfs 10  2  18 3
Volon A cre`me 10  146  67  19
Empty Tfs 0 11 0 0
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0.8, 2, and 20 Ag cm 2, respectively. The AUC’s character-
ising TransfersomeR formulations are much higher, having
values of 3100, 3682, and 6174 h% for the dosages of 0.2,
0.4, and 0.8 Ag cm 2, respectively.
3.3. Adverse side effects
In our earlier work [17], we presented typical biodistri-
bution data for the various TransfersomeR-based cortico-
steroids. Here, we re-analyse the triamcinolone-acetonide
related data with a focus on the anticipated risk/benefit ratio.
When a relatively high area–dose (f 40 Ag cm 2) is
used, approximately 20% of the triamcinolone-acetonide
derived radioactivity are retained in the skin 8 h after
application (Fig. 6, left panel); the remainder is recovered
in the body [20]. Reducing the dosage level by approxi-
mately one order of magnitude increases the amount of skin-
retained triamcinolone-acetonide based radioactivity to
90%. The extrapolated 100% limit is reached for the
epicutaneous drug dose of 1 Ag cm 2, which we have
shown will ensure a proper function in the murine ear
edema. The inner/outer skin ratio for triamcinolone-aceto-
nide correspondingly changes with the administered dose.
The drug concentration in the murine skin is much higher
than in the blood (Fig. 6, right panel) despite the fact that we
treated a relatively large proportion of the total skin area in
mice.
An improved risk/benefit ratio is also indicated by
treating the test mice with triamcinolone-acetonide in Trans-
fersomesR or in a cre`me so as to achieve an approximately
equipotent effect. The results are given in Table 1 and
demonstrate rather clearly the diminished danger of local
as well as systemic side effects of the drug in ultradeform-
able carriers. In addition to having lost weight, the animalsFig. 6. Effect of changing the applied dose per area of triamcinolone-
acetonide in TransfersomesR on the skin on the drug retention in the organ
and its main regions (left panel). The corresponding local versus systemic
drug concentration ratio is given in the right panel. The result of the linear
extrapolation is shown in the left panel as a straight line.treated with Volon AR cre`me also generally were in poorer
shape.4. Discussion
Owing to their widespread use, corticosteroids have been
incorporated into many modern drug delivery systems. For
example, Mezei et al. [4–6] as well as several other groups
[7–12] published a series of papers in which the advantages
of liposomal corticosteroids were praised. In a 1993 review,
Schaefer-Korting reiterated some of these thoughts [20]. To
date, no liposome-based corticosteroidal dermatic has actu-
ally been commercialised, however. One possible reason for
this is the lack of consistency in the alleged therapeutic
benefits of liposomal corticosteroids. It is clear that at least
some of the lipid aggregates have a beneficial effect on the
risk profile of topicals. It is unclear, however, whether this
reflects improved drug retention in the skin or else is a
consequence of the less direct effects of carrier components
upon the organ.
Phosphatidylcholine has been reported to improve indi-
rectly the bioavailability of the epidermally applied cortico-
steroids [21]; a thin lipid film in close contact with the skin
was proposed to promote stratum corneum hydration and
also to create an environment into which corticosteroids can
partition before their subsequent uptake. Lipids from the
vesicles in such scenarios were postulated to take the role of
skin permeation enhancers [16,22,23], which explains why
the experiments were often done with occluded skin.
We currently know of no direct evidence for the skin
crossing by any corticosteroid-loaded liposome: the pub-
lished data normally refer simply to the drugs applied with
such carriers or, even less directly, to the biological action of
the drug. For example, Jacobs et al. [21] reported the degree
of human skin blanching, as assessed by the vasoconstric-
tion test, to increase upon concomitant treatment with
phospholipids and different corticosteroids applied separate-
ly in commercial formulations. More relevantly, Fresta and
Publisi [11] measured 6 and 1.3 times stronger skin reflec-
tion in the 4–8 h time period after the skin treatment with
triamcinolone-acetonide in phospholipid- and skin lipid-
based formulations, respectively. Their observation needs
further verification to exclude contribution/interference
from the light-reflecting lipid suspension at the skin surface,
G. Cevc, G. Blume / Biochimica et Biophysica Acta 1614 (2003) 156–164162which in our experience, is a big problem in these kinds of
studies. Corticosteroid association with liposomes was in-
ferred [5–10] to improve the drug activity by acting as a
selective drug delivery system, and was concluded by some
researchers to depend more on the vesicle charge than on
size or the presence of membrane stiffening agents [12].
Korting et al. [24] have also concluded that liposome
encapsulation moderately improves the activity of betame-
thasone diproprionate against atopic eczema but not against
psoriasis vulgaris.
Using the mouse ear edema model with our modifica-
tions of the measurement procedure, we were able to
observe a marked difference between triamcinolone-aceto-
nide and other corticosteroids tested; further results will be
published separately. The biological action of TAC lasts
much longer than, for example, that of hydrocortisone. The
half-life for edema suppression of the latter drug is only 7–
16 h [17], while triamcinolone-acetonide has a dose-depen-
dent half-life for edema suppression of 30–90 h, depending
on the applied dosage (cf. Fig. 1).
The results were generally found to be well reproducible
in the present study, despite some temporal as well as
maximum drug effect variability. Illustrative data are given
in Fig. 7, which compares the outcome of three different
experiments with the drug in TransfersomesR and of two test
series with the drug in a lotion. A direct correlation of two
original data sets is made in the inset to this figure, whereas
in the main graph, the result of time-axis re-normalisation,Fig. 7. Robustness of the murine ear edema suppression test with
triamcinolone-acetonide as a function of time after the drug administration
on the skin in TransfersomesR (closed symbols, single dose) or in
commercial lotion (open symbols, five-fold dose). The inset shows the
original data from two experiments; the main figure compares these data
after the time axis re-normalisation for one data set (see main text body for
details) including a third set of data measured with the drug in
ultradeformable carriers. The inset has the same scale division as the main
figure panel.which aligned the first edema-suppression peak values, is
given. This shows that the main biological assay used in this
study is quite robust. The average standard deviation, how-
ever, is typically 7–50% lower for the TransfersomeR group
in comparison with commercial products.
In contrast, we believe that the vasoconstriction (skin
blanching) test is not well suited for the testing of carrier-
based dermatics. In our opinion, this is due to the inability
of relatively large carriers to cross the walls of intact blood
capillaries [25,26]. Drug carriers that have reached the
viable epidermis can therefore only reach the blood
through the lymphatic system [16,26,28,29], which ham-
pers the ability of the carrier-associated drug to induce a
strong local vasoconstriction. In contrast, dissolved drugs
or small agent aggregates from a topical lotion partition
readily into blood capillaries and are not unduly dissipated
through the lymphatic system [29]. Monomeric agents,
moreover, are prone to exert a much stronger local skin-
blanching effect and to create more pronounced pallor than
carrier-associated agents. These actions (rapid transfer into
the skin and slow transfer into the blood capillaries)
explain the faster onset of the desired edema-suppression
as well as the retardation of the less desirable vasocon-
striction observed with TransfersomeR formulations of
triamcinolone-acetonide. To our mind, the latter is actually
a sign of the drug spillover into the blood circulation (see
Fig. 6). One should not take this too seriously, however, as
it is well known that the corticosteroid dose needed to
induce peripheral vasoconstriction may be different from
that required for an intradermal therapeutic effect. FDA and
other regulatory agencies in the guidelines therefore cau-
tion researchers not to rely on blanching effect without
individual test validation.
The abovementioned problem notwithstanding, the hu-
man skin-blanching test can give results with a meaning
similar to that of the outcome of murine-ear edema-sup-
pression test [18].
One should realise, that the drug intravasation, which
precedes or accompanies any significant agent-dependent
vasoconstriction, is not required for therapeutical cortico-
steroid action. In fact, corticosteroid intravasation is highly
undesirable, as it unavoidably increases the danger of the
systemic side effects. In contrast, keeping the drug in the
cutaneous or subcutaneous tissue minimises the drug burden
in remote tissues. Monomeric drugs, which cross the walls
of the blood capillaries and then cause vasoconstriction,
therefore bring with them a much higher chance of adverse
side effects.
When a TransfersomeR is forced into an orifice, such as
an inter-corneocyte constriction in the stratum corneum, its
components redistribute non-uniformly [14]. This permits
the aggregate to accommodate to the inhomogeneous sur-
rounding stress: the components that tolerate such a stress
better are concentrated while the others are depleted from
the most deformed sites. The protruding part of each carrier
thus becomes highly deformable, thus permitting a Trans-
G. Cevc, G. Blume / Biochimica et Biophysica Acta 1614 (2003) 156–164 163fersomeR to adjust its form to the shape of the potential
pathway and to cross the otherwise non-passable constric-
tions in the skin. The ultradeformable agent carriers conse-
quently overcome the skin barrier through the hydrophilic
inter-cellular channels [26] that are too narrow to be
penetrated by other kind of lipid aggregates.
We are convinced that TransfersomesR are driven across
the skin by the water activity gradient across the stratum
corneum [27]. Such a gradient falls rather steeply with the
depth in the skin [30] and points from the surface into the
organ depth. The rate and the efficacy of the resulting
hydrotactic TransfersomeR motion are therefore indepen-
dent of the applied drug concentration. This permits the
latter to be lowered to the level fixed by the intrinsic activity
of the drug and not by the need to maximise the trans-
epidermal agent flow by keeping the superficial drug
concentration high. Formulations of corticosteroids in
TransfersomesR can thus be applied topically with an
unprecedented low agent content. The fact that Trans-
fersomeR suspensions, unlike many standard topical drug
formulations, contain no harmful skin permeation enhancers
should also contribute favourably to the drug tolerance on
the skin.
Corticosteroid-loaded TransfersomesR experience no
further inward water activity gradient when they have
reached the wet, viable epidermis [31]. Consequently, any
appreciable spontaneous carrier motion ceases in this skin
region. The viable skin hence acts as a local reservoir filled
with the carrier-associated drug. This reservoir is partially
identical to the site of the desired biological action and not
subject to the further limitation on the diffusion through the
stratum corneum. The relative drug accumulation in the skin
(Fig. 6) supports our hypothesis, being always H10% and
thus several orders of magnitude above the 0.001% reported
in Ref. [11].
The fate and the activity of the carrier-transported cortico-
steroids in the skin depend on the agent solubility in the
tissue. Triamcinolone-acetonide has a weak propensity to
leave the carrier, due to its relatively high lipophilicity. The
drug is therefore ideally suited for use in TransfersomesR.
Such a conclusion is indirectly supported by the long
biological half-life of the drug in TransfersomesR (t1/2z 6 h).
Suitably optimised TransfersomesR excel in several
respects over other vehicles for the intracutaneous drug
delivery. Triamcinolone-acetonide from TransfersomesR is
biologically active at doses at least one order of magnitude
lower than those commonly used with commercial topical
lotions/cre`mes. In contrast, the relative potency of simple
liposome-based formulations is not significantly better than
that of commercial products.
Triamcinolone-acetonide in TransfersomesR suppresses
arachidonic acid-induced skin edema longer than the mar-
keted products for topical treatment. The retardation of anti-
edema action, which would be seen when the applied drug
dose was increased, is particularly important in the low dose
range. It is also more pronounced for drugs, such astriamcinolone-acetonide, that have slow exchange rates,
and allows the formulation of very low dosed formulations
that retain a biological activity over a longer period of time
without the subsequent systemic side effects frequent with
topical lotions.
We expect that triamcinolone-acetonide in Trans-
fersomeR carrier systems will be used to the maximal daily
dose limit of 1 mg. Based upon the said dosage consider-
ations and our calculations, we infer that the intracutaneous
corticosteroid concentration will probably be below 1 Ag
g 1.
There should consequently be little intolerance of the
dosage, even for the synthetic corticosteroid, such as triam-
cinolone-acetonide, as the relative degree of drug retention
in the skin is likely to be much higher in humans with a
more favourable treated-skin to total body-weight ratio, than
in mice. With respect to the low therapeutic dose per area of
triamcinolone-acetonide in TransfersomeR formulations (at
least 10 times less dosage required than for lotion based
formulations), we expect that the danger of systemic side
effects also will be negligible.
Another advantage of using triamcinolone-acetonide in
TransfersomesR could be that the TransfersomeR formula-
tions are more reliable in their action than current topical
cre`mes and lotions. This is attested to by the relatively small
standard deviations in the experiments with TransfersomesR
versus commercially available cre`mes.
In this paper, we have supplied conclusive evidence for
the efficacy and therapeutic value of a new formulation of
the synthetic corticosteroid triamcinolone-acetonide in ultra-
deformable TransfersomesR. With TransfersomesR, we
thus introduced a new mechanism for therapeutically treat-
ing the skin disease. We expect multiple advantages of such
treatment, including a faster onset of anti-edema effects;
longer times of action, a biological action that is unaffected
by mechanical abrasion, and most importantly, the ability to
drastically (by at least a factor of 10) reduce the necessary
dosage needed to achieve therapeutic effects. This will
increase the risk/benefit ratio and potentially allow the use
of triamcinolone-acetonide or a related drug in Trans-
fersomesR in situations in which such drugs were not
previously considered due to the danger of adverse side
effects. The use of TransfersomesR on the skin therefore
offers unprecedented opportunities for well-controlled and
modern topical medication, not just for corticosteroids, but
also for a variety of other low molecular weight and
macromolecular therapeutics [32]. The bio-efficacy results
reported in this work, moreover, relate to the recent work by
Dr. Bouwstra, who also uses elastic vesicles comprising a
phospholipid and a surfactant [33,34].Acknowledgements
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